Mainz Biomed NV

Quantum Cyber N.V. (QUCY) presents its strategic pivot to autonomous defense, showcasing battle-tested platforms, integrated IP, and US manufacturing capabilities.

Quantum Cyber N.V. has completed the acquisition of a U.S.-based manufacturing facility in Bridgeport, Connecticut, for $2.3 million, marking a significant step in its transition to vertical integration.

Quantum Cyber N.V. announces definitive agreements to acquire a 50,000 sq ft manufacturing facility and equipment in Bridgeport, Connecticut, for $3.2 million, advancing its strategy for domestic defense manufacturing.

Quantum Cyber N.V. has dismissed Reliant CPA PC and appointed Haskell & White LLP as its new independent auditor.

Quantum Cyber N.V. has secured exclusive worldwide rights to Project LightShift's quantum photonic array technology for defense drone applications.

Quantum Cyber N.V. has amended its intellectual property license agreement with BP United Inc., shifting from a supply agreement to manufacturing and consulting services, and retaining a $5 million payment for its own production ramp-up.

Mainz Biomed slashes legacy cancer programs, sells ColoAlert IP, lines up $6M preferred financing that could exceed 95% dilution, and seeks shareholder approval to rebrand as Quantum Cyber N.V.

Quantum Cyber N.V. director Peter O'Rourke acquired 112,859 stock options with an exercise price of $1.45.

Quantum Cyber N.V. director Avraham Ben-Tzvi reported the acquisition of 137,141 ordinary shares on May 8, 2026.

Director David Natan reported the acquisition of 137,141 ordinary shares of Quantum Cyber N.V. on May 8, 2026.

CEO David E. Lazar acquired 2,000,000 additional preferred shares in Quantum Cyber N.V. following shareholder approval of key corporate actions.

Mainz Biomed N.V. Director David E. Lazar acquired $3 million in preferred shares, with an additional $3 million pending, contingent on significant stockholder approvals including a reverse stock split and board changes.

Mainz Biomed N.V. Chief Financial Officer William J Caragol was granted 290,000 ordinary shares under the company's 2025 Omnibus Incentive Plan.

Quantum Cyber N.V. has issued a proxy statement for its June 29, 2026, annual general meeting to vote on board appointments, remuneration policy amendments, and a strategic pivot into quantum-ready autonomous defense platforms.

Mainz Biomed N.V. calls an extraordinary shareholder meeting to approve a significant capital raise, a reverse stock split, a name change to Quantum Cyber N.V., and a new board, signaling a major strategic pivot towards quantum computing.

Investor David E. Lazar has acquired a 97.4% stake in Mainz Biomed N.V. and has been appointed as the new Chief Executive Officer.

Kevin Michael Donahue has reported increasing his beneficial ownership in Mainz Biomed N.V. to 10.7% of common stock.

Kevin Michael Donahue has reported a significant beneficial ownership of 10.7% in Mainz Biomed N.V. common stock.

Armistice Capital and Steven Boyd have disclosed a 9.99% beneficial ownership stake in Mainz Biomed N.V., holding 723,092 ordinary shares.

Armistice Capital, LLC and Steven Boyd have filed an amended Schedule 13G, revealing a shared beneficial ownership of 9.99% of MAINZ BIOMED N.V.'s Ordinary Shares.

Investment firm Armistice Capital, LLC and its managing member Steven Boyd have disclosed a significant passive ownership stake of 9.99% in MAINZ BIOMED N.V. as of December 31, 2024.